Table 1.
2015 Guideline | 2011 Guideline | |
---|---|---|
THERAPEUTIC AGENT | ||
Pirfenidone | Conditional recommendation for use* | Weak recommendation against use |
Nintedanib | Conditional recommendation for use | Not addressed |
Antiacid therapy | Conditional recommendation for use | Weak recommendation for use |
Phosphodiesterase-5 inhibitor (sildenafil) | Conditional recommendation against use | Not addressed |
Dual endothelin receptor antagonists (bosentan, macitentan) | Conditional recommendation against use | Strong recommendation against use |
N-acetylcysteine (NAC) | Conditional recommendation against use | Weak recommendation against use |
Azathioprine + corticosteroids + NAC | Strong recommendation against use | Weak recommendation against use |
Warfarin | Strong recommendation against use | Weak recommendation against use |
Imatinib | Strong recommendation against use | Not addressed |
Selective endothelin receptor antagonist (ambrisentan) | Strong recommendation against use | Not addressed |
Conditional recommendations are synonymous with weak recommendations